

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/031380 A1

(43) International Publication Date
09 March 2023 (09.03.2023)

(51) International Patent Classification:

A61K 38/26 (2006.01) A61P 3/04 (2006.01)
A61K 38/00 (2006.01) A61P 5/48 (2006.01)

(21) International Application Number:

PCT/EP2022/074420

(22) International Filing Date:

02 September 2022 (02.09.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

21194879.9 03 September 2021 (03.09.2021) EP
22160234.5 04 March 2022 (04.03.2022) EP

(71) Applicant: ZEALAND PHARMA A/S [DK/DK]; Sydmarken 11, 2860 Søborg (DK).

(72) Inventor: AGERSNAP, Mikkel Askjær; c/o Zealand Pharma A/S, Sydmarken 11, 2860 Søborg (DK).

(74) Agent: MILTON, Tamara; D Young & Co LLP, 120 Holborn, London EC1N 2DY (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: DOSAGE REGIME

(57) Abstract: The invention relates to a dosage regime for compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors for use in the treatment of obesity and related conditions.

WO 2023/031380 A1